Equities

Bioceltix SA

Bioceltix SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)67.50
  • Today's Change1.40 / 2.12%
  • Shares traded1.22k
  • 1 Year change+6.13%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bioceltix SA is a Poland-based biopharmaceutical company, which operates in the field of veterinary medicine. The Company deal with the development of candidates for veterinary medicinal products based on the immunomodulatory properties of mesenchymal stem cells used as the active substance of the drug. Entity's products are intended for the treatment of companion animals. The Company carry out research and development works, which enable clinical trials and full registration of medicinal products in the European Medicines Agency, as is the case with medicines and drugs administered to humans.

  • Revenue in PLN (TTM)0.00
  • Net income in PLN-12.73m
  • Incorporated2018
  • Employees--
  • Location
    Bioceltix SAul. Bierutowska 57-59, bud. IIIWROCLAW 51-317PolandPOL
  • Phone+48 718808771
  • Fax+48 717345509
  • Websitehttps://bioceltix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Genomtec SA19.00k-13.35m153.22m----14.59--8,064.40-1.32-1.320.00180.8570.001424.230.0095---95.96---115.26---12,973.68---70,247.37--4.05-31.750.1413---81.72---126.20------
Sds Optic SA530.40k-7.39m154.58m----22.04--291.44-1.30-1.300.09281.190.054-5.912.11---75.38---94.39--167.64---1,395.87--4.85--0.00---99.59---85.26------
Poltreg SA1.40m-13.55m227.11m23.00--2.60--162.34-2.91-2.910.30018.770.011251.2227.4361,494.50-10.82-6.51-12.42-7.35-811.65-391.38-968.62-449.243.87--0.0856--40.04---588.92--214.26--
Molecure SA1.31m-18.31m244.12m111.00--1.55--186.56-1.17-1.170.08479.340.0085--0.281811,788.92-11.942.52-12.472.64-25.7697.54-1,398.8612.84----0.0434---18.85237.24-19.67---24.82--
Mabion SA151.68m41.27m266.68m226.006.462.265.501.762.552.559.387.290.76914.849.12671,146.0020.93-7.1931.17-16.7975.5458.1027.21-14.271.518.350.2331---7.50--77.94--40.86--
Bioceltix SA0.00-12.73m278.74m----19.59-----3.45-3.450.003.450.00170.52-----112.58---140.07----------5.96--0.0071-------102.87------
BIOTON SA181.64m2.28m300.95m358.00132.310.49638.081.660.02650.02652.127.060.22280.949318.41507,363.100.279-1.990.3437-2.4740.1145.331.25-8.610.29331.900.1018---22.10-5.5160.10-38.690.3284--
Synthaverse SA58.61m4.76m319.78m239.0072.363.0628.085.460.06770.06770.83411.600.27321.662.76245,217.602.223.532.554.3260.0055.628.129.590.97054.470.3834--16.3212.66-21.76--111.77--
Captor Therapeutics SA13.20m-70.58m336.79m104.00--5.36--25.51-16.42-16.423.0414.900.1256--3.59126,932.70-67.13---82.96--52.28---534.69------0.0518--44.15---96.65------
Data as of Apr 26 2024. Currency figures normalised to Bioceltix SA's reporting currency: Polish New Zloty PLN

Institutional shareholders

2.17%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Dec 202389.70k2.17%
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.